Selected research
Industry Growth & Trends
Global Diagnostic Nuclear Drug Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Diagnostic Nuclear Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Diagnostic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Diagnostic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Diagnostic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Diagnostic Nuclear Drug market include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Diagnostic Nuclear Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Diagnostic Nuclear Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Diagnostic Nuclear Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Diagnostic Nuclear Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Diagnostic Nuclear Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Diagnostic Nuclear Drug Market by Company
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
SIEMENS
Dongcheng
Eli Lilly
Novartis
China Isotope & Radiation
Diagnostic Nuclear Drug Segment by Type
Tc-99m
F-18
Other
Diagnostic Nuclear Drug Segment by Application
Oncology
Cardiology
Other
Diagnostic Nuclear Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Diagnostic Nuclear Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tc-99m
- F-18
- Other
Applications
- Oncology
- Cardiology
- Other
Companies covered
- Bracco Imaging
- Cardinal Health
- Curium Pharma
- GE Healthcare
- Jubilant Pharma
- Lantheus
- SIEMENS
- Dongcheng
- Eli Lilly
- Novartis
- China Isotope & Radiation
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Diagnostic Nuclear Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Diagnostic Nuclear Drug Market Size by Region (2021-2032)
- 1.4.1 Global Diagnostic Nuclear Drug Market Size by Region (2021-2026)
- 1.4.2 Global Diagnostic Nuclear Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Diagnostic Nuclear Drug Market Size (2021-2032)
- 1.5.1 North America Diagnostic Nuclear Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Diagnostic Nuclear Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Diagnostic Nuclear Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Diagnostic Nuclear Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Diagnostic Nuclear Drug Market Size Growth Rate (2021-2032)
2 Diagnostic Nuclear Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Tc-99m
- 2.1.2 F-18
- 2.1.3 Other
- 2.2 Global Diagnostic Nuclear Drug Market Size by Type
- 2.2.1 Global Diagnostic Nuclear Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Diagnostic Nuclear Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Diagnostic Nuclear Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Diagnostic Nuclear Drug Market Size by Regions
- 2.3.1 North America Diagnostic Nuclear Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Diagnostic Nuclear Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Diagnostic Nuclear Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Diagnostic Nuclear Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Diagnostic Nuclear Drug Market Size Breakdown by Type (2021-2026)
3 Diagnostic Nuclear Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Oncology
- 3.1.2 Cardiology
- 3.1.3 Other
- 3.2 Global Diagnostic Nuclear Drug Market Size by Application
- 3.2.1 Global Diagnostic Nuclear Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Diagnostic Nuclear Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Diagnostic Nuclear Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Diagnostic Nuclear Drug Market Size by Regions
- 3.3.1 North America Diagnostic Nuclear Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Diagnostic Nuclear Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Diagnostic Nuclear Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Diagnostic Nuclear Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Diagnostic Nuclear Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Diagnostic Nuclear Drug Industry Trends
- 4.2 Diagnostic Nuclear Drug Industry Drivers
- 4.3 Diagnostic Nuclear Drug Industry Opportunities and Challenges
- 4.4 Diagnostic Nuclear Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Diagnostic Nuclear Drug Revenue (2021-2026)
- 5.2 Global Diagnostic Nuclear Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Diagnostic Nuclear Drug Key Company Headquarters & Area Served
- 5.4 Global Diagnostic Nuclear Drug Company, Product Type & Application
- 5.5 Global Diagnostic Nuclear Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Diagnostic Nuclear Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Diagnostic Nuclear Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Diagnostic Nuclear Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Bracco Imaging
- 6.1.1 Bracco Imaging Company Information
- 6.1.2 Bracco Imaging Business Overview
- 6.1.3 Bracco Imaging Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Bracco Imaging Diagnostic Nuclear Drug Product Portfolio
- 6.1.5 Bracco Imaging Recent Developments
- 6.2 Cardinal Health
- 6.2.1 Cardinal Health Company Information
- 6.2.2 Cardinal Health Business Overview
- 6.2.3 Cardinal Health Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Cardinal Health Diagnostic Nuclear Drug Product Portfolio
- 6.2.5 Cardinal Health Recent Developments
- 6.3 Curium Pharma
- 6.3.1 Curium Pharma Company Information
- 6.3.2 Curium Pharma Business Overview
- 6.3.3 Curium Pharma Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Curium Pharma Diagnostic Nuclear Drug Product Portfolio
- 6.3.5 Curium Pharma Recent Developments
- 6.4 GE Healthcare
- 6.4.1 GE Healthcare Company Information
- 6.4.2 GE Healthcare Business Overview
- 6.4.3 GE Healthcare Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 GE Healthcare Diagnostic Nuclear Drug Product Portfolio
- 6.4.5 GE Healthcare Recent Developments
- 6.5 Jubilant Pharma
- 6.5.1 Jubilant Pharma Company Information
- 6.5.2 Jubilant Pharma Business Overview
- 6.5.3 Jubilant Pharma Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Jubilant Pharma Diagnostic Nuclear Drug Product Portfolio
- 6.5.5 Jubilant Pharma Recent Developments
- 6.6 Lantheus
- 6.6.1 Lantheus Company Information
- 6.6.2 Lantheus Business Overview
- 6.6.3 Lantheus Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Lantheus Diagnostic Nuclear Drug Product Portfolio
- 6.6.5 Lantheus Recent Developments
- 6.7 SIEMENS
- 6.7.1 SIEMENS Company Information
- 6.7.2 SIEMENS Business Overview
- 6.7.3 SIEMENS Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 SIEMENS Diagnostic Nuclear Drug Product Portfolio
- 6.7.5 SIEMENS Recent Developments
- 6.8 Dongcheng
- 6.8.1 Dongcheng Company Information
- 6.8.2 Dongcheng Business Overview
- 6.8.3 Dongcheng Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Dongcheng Diagnostic Nuclear Drug Product Portfolio
- 6.8.5 Dongcheng Recent Developments
- 6.9 Eli Lilly
- 6.9.1 Eli Lilly Company Information
- 6.9.2 Eli Lilly Business Overview
- 6.9.3 Eli Lilly Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Eli Lilly Diagnostic Nuclear Drug Product Portfolio
- 6.9.5 Eli Lilly Recent Developments
- 6.10 Novartis
- 6.10.1 Novartis Company Information
- 6.10.2 Novartis Business Overview
- 6.10.3 Novartis Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Novartis Diagnostic Nuclear Drug Product Portfolio
- 6.10.5 Novartis Recent Developments
- 6.11 China Isotope & Radiation
- 6.11.1 China Isotope & Radiation Company Information
- 6.11.2 China Isotope & Radiation Business Overview
- 6.11.3 China Isotope & Radiation Diagnostic Nuclear Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 China Isotope & Radiation Diagnostic Nuclear Drug Product Portfolio
- 6.11.5 China Isotope & Radiation Recent Developments
7 North America
- 7.1 North America Diagnostic Nuclear Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 7.3 North America Diagnostic Nuclear Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Diagnostic Nuclear Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 8.3 Europe Diagnostic Nuclear Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Diagnostic Nuclear Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Diagnostic Nuclear Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Diagnostic Nuclear Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 10.3 South America Diagnostic Nuclear Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Diagnostic Nuclear Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Diagnostic Nuclear Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Diagnostic Nuclear Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst